Experimental eye injection shows promise in restoring neural signals for blindness

 

A pioneering clinical trial has demonstrated that a light-sensitive chemical injection can successfully trigger vision-related brain activity in patients with advanced retinal blindness, offering a potential new pathway for restoring sight.

Human Trial Targets Advanced Vision Loss

The Phase 1 clinical trial, known as ABACUS-1, involved six adults suffering from late-stage retinitis pigmentosa. This inherited condition typically destroys the eye’s primary light sensors—rods and cones—eventually leading to total blindness.

Led by Dr. Robert J. Casson, an ophthalmologist at Royal Adelaide Hospital, the study focused on the safety of KIO-301, a "photoswitch" molecule designed to bypass damaged photoreceptors and directly activate surviving retinal cells.

A "Molecular Switch" for the Eye

KIO-301 utilizes an azobenzene photoswitch that changes shape when exposed to light. This mechanism aims to turn retinal ganglion cells—which usually only transmit data—into primary light sensors themselves.

Shutterstock

By targeting these surviving downstream cells rather than specific genetic mutations, the treatment could theoretically work for a wide range of inherited retinal diseases, regardless of the underlying genetic cause.

Brain Scans Confirm Signal Transmission

While the primary goal was safety, researchers observed intriguing physiological responses. Functional MRI (fMRI) scans conducted after the injections revealed blood-oxygen changes in the visual cortex of several participants. These scans suggest that the drug successfully enabled the eyes to send light-triggered signals to the brain, particularly within the first 48 to 72 hours following treatment.

Safety and Limitations

The study reported no serious adverse effects or drug-related inflammation, confirming the short-term safety of the intravitreal injection. However, researchers cautioned that the functional results were uneven. While some participants showed improvements in mobility tasks—such as finding doors or navigating rooms—these effects often faded over the 30-day observation period.

As a small-scale, open-label study without a control group, the trial cannot yet prove that the drug provides "useful" or "everyday" vision.

Future Outlook

“The results provide evidence of short-term ocular safety and feasibility,” said Dr. Casson, while emphasizing the need for larger trials to determine if these neural signals can translate into reliable vision.

A Phase 2 study is currently being organized to test higher, repeated doses. This next stage will use a randomized control group to more accurately measure whether the treatment can provide durable, long-term functional benefits for those living in total darkness.

The study is published in Nature Medicine